Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Wellness Today St. Kitts & Nevis.
May 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |||
| 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| 26 | 27 | 28 | 29 | 30 | 31 |
June 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 |
July 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 |
Press releases published on May 12, 2025
Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 12, 2025
REDWOOD CITY, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT to address mast cell driven …
Stereotaxis Reports 2025 First Quarter Financial Results
GlobeNewswire
·
May 12, 2025
ST. LOUIS, May 12, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first quarter ended March 31, 2025. “We’ve …
Xenon Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 12, 2025
– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment expected to complete in the next few months with topline data anticipated in early 2026 – Phase 3 azetukalner X-NOVA3 MDD and Phase 3 BPD studies on track to initiate mid-year – Results from …
Assertio Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 12, 2025
First Quarter Total Net Product Sales of $26.0 Million, In Line with 2025 Outlook Provides Update on Long-Term Business Strategy Designed to Create Sustainable Near-Term Growth and Increased Long-Term Value LAKE FOREST, Ill., May 12, 2025 (GLOBE NEWSWIRE) …
Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 12, 2025
Positive initial Phase 2 proof-of-concept data for NDV-01 at AUA 2025 showing a 90% overall response rate at any time in non-muscle invasive bladder cancer (US prevalence 600K patients) The Phase 2 study for NDV-01 continues with updates at 6, 9 and 12 …
Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer
GlobeNewswire
·
May 12, 2025
- Dr. Nicholas Botwood comes to Syndax from BMS and brings 25 years of industry experience leading drug development, R…
Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board
GlobeNewswire
·
May 12, 2025
CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that the U.S. Court of Appeals for the Federal Circuit affirmed-in-part and vacated-in-part the Patent Trial and …
MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update
GlobeNewswire
·
May 12, 2025
MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update Continued to make significant progress with the development of the Nanobody® sonelokimab across portfolio of indications, including Phase 3 studies in …
Siren Biotechnology to Present Universal AAV Immuno-Gene Therapy Data at the 2025 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
GlobeNewswire
·
May 12, 2025
SAN FRANCISCO, May 12, 2025 (GLOBE NEWSWIRE) -- Siren Biotechnology Inc., pioneers of Universal AAV Immuno-Gene Therapy for Cancer, today announced that it will present new scientific data at the 2025 American Society of Gene and Cell Therapy (ASGCT) …
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
GlobeNewswire
·
May 12, 2025
TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and …
Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight
GlobeNewswire
·
May 12, 2025
New York, USA, May 12, 2025 (GLOBE NEWSWIRE) -- Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight The blood cancer market is experiencing robust growth, driven by rising incidence …
Heroes on the Water Observes National Police Week Focusing on Officer Wellness, Cumulative PTSD
GlobeNewswire
·
May 12, 2025
Allen, Texas, May 12, 2025 (GLOBE NEWSWIRE) -- National Police Week is a time to remember officers who have made the ultimate sacrifice, and a time to recognize the everyday cost of service carried by those still on the job. This year, Heroes on the Water …
The Joint Commission and National Quality Forum announce recipients of 2024 Eisenberg Patient Safety and Quality Awards
GlobeNewswire
·
May 12, 2025
OAKBROOK TERRACE, Illinois, May 12, 2025 (GLOBE NEWSWIRE) -- The Joint Commission and the National Quality Forum (NQF) today announced the recipients of the 2024 John M. Eisenberg Patient Safety and Quality Awards. The Eisenberg Awards, named in honor of …
PacBio Board Independent Investigation Concludes Allegations Unsubstantiated
GlobeNewswire
·
May 12, 2025
MENLO PARK, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced that the Special Committee of its Board of Directors (the “Special Committee”) has concluded its independent investigation into previously disclosed allegations from …
Services-Conseils en Ergonomie devient ERGOVIA
GlobeNewswire
·
May 12, 2025
SHERBROOKE, Québec, 12 mai 2025 (GLOBE NEWSWIRE) -- SCE Services-Conseils en Ergonomie devient ERGOVIA. Ce changement de nom s’accompagne d’une toute nouvelle image de marque. Cette évolution s'inscrit dans une démarche stratégique visant à mieux refléter …
Nurses Speak Out on Burnout, Balance, and the Future of the Profession in New Survey
GlobeNewswire
·
May 12, 2025
DALLAS, May 12, 2025 (GLOBE NEWSWIRE) -- While 75% of nurses report being satisfied with their career choice, many still face significant strain due to burnout, mental health challenges, and staffing issues, according to a new survey by AMN Healthcare, the …
InBrain Pharma Secures €1.8 Million in Funding for the PERCEPAR Project under France 2030’s “First Factory” Initiative to Industrialize Anaerobic Dopamine Production for Parkinson’s Disease
GlobeNewswire
·
May 12, 2025
InBrain Pharma Secures €1.8 Million in Funding for the PERCEPAR Project under France 2030’s “First Factory” Initiative to Industrialize Anaerobic Dopamine Production for Parkinson’s Disease Lille, May 12, 2025 – InBrain Pharma, a clinical stage biotech …
Porch Light Health Acquires Comprehensive Behavioral Health Center to Expand Access to Full-Spectrum Addiction Treatment
GlobeNewswire
·
May 12, 2025
DENVER, May 12, 2025 (GLOBE NEWSWIRE) -- Porch Light Health, the largest addiction medicine practice in Colorado, offering outpatient Medications for Addiction Treatment (MAT) at more than 60 treatment locations, is proud to announce the acquisition of …
Lancement de campagne de prévention au tabagisme chez les jeunes âgé·es de 11 à 15 ans : Laisse pas ta vie partir en fumée
GlobeNewswire
·
May 12, 2025
MONTRÉAL, 12 mai 2025 (GLOBE NEWSWIRE) -- Le RSEQ (Réseau du sport étudiant du Québec) lance Laisse pas ta vie partir en fumée, une campagne annuelle de prévention à l’initiation du tabagisme visant à sensibiliser les jeunes âgés de 11 à 15 ans. Elle vise …
Bioxytran Completes Dose Optimization of Antiviral, ProLectin-M
GlobeNewswire
·
May 12, 2025
BOSTON, MASSACHUSETTS, May 12, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing novel antiviral therapies, today announced the successful completion of the dose optimization of its …